Roche Bullish Despite Biosimilars Battering
Pharma Sales Down By 7% in Q4
Executive Summary
Its older oncology products are sinking but the Swiss major is confident about coming through COVID-19 in a strong position.
You may also be interested in...
Roche’s Actemra Scores New Indication In Rare Autoimmune Disease
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
Roche Takes Advantage Of COVID-19 Testing Rush
Roche’s sales in 2020 increased by 1%, at constant exchange rates, to CHF 58.3bn, led by 14% growth in its diagnostics division.
Don’t Write Actemra Off Yet: Roche Drug Found To Be Lifesaving In COVID-19
After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.